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Abstract
MCP-1/CCL2 plays an important role in the initiation and progression of cancer. Since tumor cells produce MCP-1, they are
considered to be the main source of this chemokine. Here, we examined whether MCP-1 produced by non-tumor cells
affects the growth and lung metastasis of 4T1 breast cancer cells by transplanting them into the mammary pad of WT or
MCP-12/2 mice. Primary tumors at the injected site grew similarly in both mice; however, lung metastases were markedly
reduced in MCP-12/2 mice, with significantly longer mouse survival. High levels of MCP-1 mRNA were detected in tumors
growing in WT, but not MCP-12/2 mice. Serum MCP-1 levels were increased in tumor-bearing WT, but not MCP-12/2 mice.
Transplantation of MCP-12/2 bone marrow cells into WT mice did not alter the incidence of lung metastasis, whereas
transplantation of WT bone marrow cells into MCP-12/2 mice increased lung metastasis. The primary tumors of MCP-12/2
mice consistently developed necrosis earlier than those of WT mice and showed decreased infiltration by macrophages and
reduced angiogenesis. Interestingly, 4T1 cells that metastasized to the lung constitutively expressed elevated levels of MCP-
1, and intravenous injection of 4T1 cells producing a high level of MCP-1 resulted in increased tumor foci in the lung of WT
and MCP-12/2 mice. Thus, stromal cell-derived MCP-1 in the primary tumors promotes lung metastasis of 4T1 cells, but
tumor cell-derived MCP-1 can also contribute once tumor cells enter the circulation. A greater understanding of the source
and role of this chemokine may lead to novel strategies for cancer treatment.
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Introduction
Leukocytes infiltrate a number of human and mouse cancers
[1,2]. Although the composition of tumor infiltrating leukocytes
and the role they play may vary in each tumor, they are generally
immunosuppressive and provide a microenvironment that favors
tumor growth. Therefore, identifying the mechanisms by which
immunosuppressive leukocytes are recruited into tumors is critical
and clinically relevant.
Monocyte chemoattractant protein-1 (MCP-1)/CCL2 is a
chemokine with potent monocyte chemotactic activity. It was
initially purified from the culture supernatant of a human
malignant glioma [3] and a monocytic leukemic cell line [4],
and was later demonstrated to be identical to the previously
described tumor cell-derived chemotactic factor [5]; thus, tumor
cells are a source of MCP-1. Earlier animal studies using MCP-1-
transfected tumor cells provided both anti- and pro-tumor effects
of MCP-1 [6–9]; however, accumulating evidence now strongly
suggest that the production of MCP-1 by tumors is responsible for
the recruitment of immunosuppressive macrophages that promote
tumor growth. In a chemically induced skin papilloma model, the
number of papillomas in MCP-1-deficient mice was lower
compared to that in WT mice [10]. A vital role of MCP-1 in
the initiation and progression of colitis-associated colon carcino-
genesis was demonstrated by using mice deficient in the MCP-1
receptor CCR2 or MCP-1 blocking agents [11]. In addition,
neutralization of MCP-1 resulted in reduced growth of prostate
cancer [12–14], breast cancer [15] and lung cancer [16] in mice.
Thus, MCP-1 is a candidate molecular target of cancer treatment
[17].
Tumor tissues contain a variety of non-tumor stromal cells,
including fibroblasts, endothelial cells and inflammatory cells.
These tumor stromal cells provide the soil in which tumor cells
grow, invade and metastasize [18–20]. Although tumor cells may
be the major source of MCP-1 in the tumor microenvironment as
described above, stromal cells also have the capacity to produce
MCP-1. In fact, stromal MCP-1 has been implicated in the
recruitment of tumor-associated macrophage and subsequent
breast cancer progression [21,22]. However, the relative contri-
bution of stromal cells to the production of MCP-1 and subsequent
tumor progression has not been experimentally evaluated.
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The 4T1 breast cancer cells were isolated from a spontaneous
mammary tumor of a Balb/cC3H mouse. When the cells are
orthotopically injected into mammary pads of Balb/c mice, they
form tumors and metastasize spontaneously to tissues, such as
lung, liver and bone, providing an excellent model to elucidate the
mechanisms involved in tumor growth and metastasis [23].
In the present study, we aimed to define the contribution of
stromal cell-derived MCP-1 to tumor progression by transplanting
4T1 cells into the mammary pad of WT or MCP-1-deficient
(MCP-12/2) mice. Our results indicate that stromal cells are the
main source of MCP-1 in 4T1 tumors and stromal cell-derived
MCP-1 promotes spontaneous lung metastasis of 4T1 cells. This
MCP-1 effect appears to be due to increased recruitment of
macrophages and increased angiogenesis in the primary tumor.
Interestingly, the expression of MCP-1 was elevated in 4T1 cells
that metastasized to the lung and intravenous injection of 4T1 cells
producing a high level of MCP-1 resulted in a higher number of
tumor foci in the lung of WT and MCP-12/2 mice, suggesting
that the tumor cell-derived MCP-1 also promotes lung metastasis
by supporting the tumor cell survival, seeding and growth in the
lung. A greater understanding of the role for this chemokine in
cancer development may lead to novel strategies for cancer
treatment.
Materials and Methods
Cell lines
4T1 and Lewis lung carcinoma (LLC) cells (ATCC, Manassas,
VA) were cultured in RPMI 1640 (Lonza, Walkersville, MD)
supplemented by 10% fetal bovine serum (FBS, HyClone, Rogan,
UT), 2 mM L-glutamine, penicillin/streptomycin and sodium
pyruvate. To obtain cell-free culture supernatants, 16105 4T1 or
LLC were seeded into 12-well tissue culture plates. After overnight
incubation at 37uC, medium was removed and 1 ml of fresh
medium was added and incubated at 37uC for 24 hrs in the
presence or absence of 1 or 10 ng/ml tumor necrosis factor a
(TNFa, R&D Systems, Minneapolis, MN) or 100 ng/ml lipopoly-
saccharide (LPS, Sigma-Aldrich, St. Louis, MO). Cell-free culture
supernatants were obtained and kept at 280uC until use.
Mice
The generation of MCP-12/2 mice was previously described
[24]. The genetic background of MCP-12/2 mice was converted
to a Balb/c background using the speed congenics service
provided by the Laboratory Animal Sciences Program (LASP),
SAIC-Frederick, Frederick, MD. Wild type Balb/c mice were
obtained from Charles River, Frederick, MD.
Tumor transplantation model
4T1 cells were grown to 50 to 80% confluence. Before injection,
cells were detached with 0.2% trypsin-EDTA, washed once with
medium, three times with PBS and resuspended in PBS at 56105/
ml. Two hundred ml of cell suspension (16105 cells) were injected
into the 2nd mammary pad of female mice. Mice were euthanized
at different time points. Tumors were excised and fixed in 10%
formalin or frozen in O.C.T. compound. Lungs were perfused
with Bouin’s solution and then fixed in the same solution. Blood
was drawn by heart puncture. Sera were isolated and stored at
280uC until use. For experimental metastasis assays, cells were
resuspended in PBS at 2.56106/ml or 26105/ml and 0.2 ml
(56105 cells or 46104 cells) were injected intravenously via tail
vein.
To obtain tumor cells from the metastatic tumor nodules in the
lung, well isolated tumor nodules were excised, minced, and
digested with collagenase VI (Sigma-Aldrich, St. Louis, MO) for
3 hours at room temperature. After removal of tissue debris, cells
were rinsed with RPMI 1640 containing 10% FBS, and then
plated in a tissue culture plate. Cells were passed for 5 generations
at 1:5 before used. At this stage, the mutated MCP-1 allele was no
longer detectable by PCR in tumor cells harvested from the lung
of MCP-12/2 mice, indicating that there was no significant
contamination by host cells.
Generation of bone marrow (BM) chimeric mice
Female WT and MCP-12/2 mice were treated with sulfameth-
oxazole/trimethoprim for two weeks. The mice were irradiated
with 800-rads X-rays and then intravenously injected with 56106
BM cells collected from femurs of either WT or MCP-12/2 mice.
Four groups of chiemric mice were generated: WT to WT, MCP-
12/2 to WT, WT to MCP-12/2, and MCP-12/2 to MCP-12/2.
To evaluate the efficiency of BM reconstitution, BM cells were
collected from femurs of representative mice at the harvest.
Genomic DNA was isolated and subjected to Southern blotting.
Northern and Southern blotting
Northern blot and Southern blot analyses were performed as
described [24,25]. Filters were hybridized at 42uC overnight in
50% formamide, 56 SSC, 56 Denhardt’s solution, 50 mg/ml
sheared-denatured salmon sperm DNA, 1% SDS, and
l6106 dpm/ml of 32P-labeled cDNA probe (Perkin Elmer, Cam-
bridge, MA). Filters were washed twice with 26 SSC, 0.5% SDS
at room temperature for 15 min and 0.16 SSC, 0.5% SDS at
60uC for 30 min prior to autoradiographic exposure.
ELISA
The concentrations of MCP-1 were measured in the Lympho-
kine Testing Laboratory, Clinical Services Program, SAIC-
Frederick, Frederick, MD, with an ELISA kit specific for mouse
MCP-1 (R&D Systems).
RT-PCR
Total RNA was isolated by TRIzol (Ambion-Life Technologies,
Carlsbad, CA) and treated with TURBO DNase (Ambion-Life
Technologies). RT-PCR was performed using the Easy-A One-
Tube RT-PCR Kit (Agilent Technologies, Santa Clara, CA) and
100 ng total RNA. Annealing temperature was 52uC for CCR2,
and 60uC for b-actin. The primer sequences were as follows:
mouse CCR2 forward, 59-GGTCATGATCCCTATGTGG-39;
mouse CCR2 reverse, 5-CTGGGCACCTGATTTAAAGG-39
[26], mouse b-actin forward, 59-TGTGATGGTGG-
GAATGGGTGAG-39; mouse b-actin reverse, 59-TTTGATGT-
CACGCACGATTTCC-39.
Immunohistochemistry
Tissues were embedded in Tissue-Tek OCT compound and
then frozen in liquid nitrogen. Seven-micron cryostat sections were
prepared, air-dried and then fixed in ice-cold acetone. After
treatment with 10% normal goat serum in Tris-buffered saline
containing 0.1% Tween 20 (TBS-T) for 20 min at room
temperature, tissue sections were incubated with rat monoclonal
antibody against F4/80 (AbD Serotec, Raleigh, NC), CD31
(Biolegend, San Diego, CA) or control IgG (5 mg/ml) for 1 h at
room temperature. After washing with TBS-T, the sections were
incubated with Alexa Flour 647-labelled anti-rat IgG (Invitrogen,
Carlsbad, CA) and Alexa Flour 488-labelled anti-pan cytokeratin
(eBioscience) for 30 min at room temperature. The expression of
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each molecule was analyzed by the FV 1000 Confocal microscope
system (Olympus, Tokyo, Japan).
FACS analysis
4T1 cells were grown to 80% confluent in T-75 flasks. Cells
were harvested using 0.02% trypsin-EDTA (Life Technologies),
washed, and then stained by a monoclonal antibody against
CCR2 labeled by PE (R&D Systems). Tumors were excised and
digested by collagenase IV for 2 hrs at room temperature. Cell
suspension was filtered through a 70 mm nylon mesh, followed by
depletion of red blood cells with ACK solution. Cells were stained
by monoclonal antibodies against mouse CD45 labeled by
PECy5.5 (BD Biosciences, San Jose, CA), CD11b labeled by PE
(eBioscience, San Diego, CA), Ly6G labeled by FITC
(eBioscience), F4/80 labeled by FITC (eBioscience), or CD206
labeled by APC (BioLegend), and the expression of each molecule
was analyzed using a FACScan flow cytometer (BD Biosciences).
Statistical analysis
Statistical analysis was performed by Student’s t-test or Log-
rank (Mantel-Cox) test, using the GraphPad Prism, Version 4 and
5, GraphPad Software, San Diego, CA. A value of p,0.05 was
considered to be statistically significant.
Ethics Statement
The experimental protocols of this study were approved by the
Frederick National Laboratory for Cancer Research Animal Care
and Use Committee, Frederick, MD.
Results
Spontaneous lung metastasis of 4T1 cells was reduced in
MCP-12/2 mice
We first examined the expression and production of MCP-1 by
4T1 cells. As shown in Figure 1A and B, 4T1 cells constitutively
expressed a low level of MCP-1 mRNA and protein. The
production of MCP-1 was significantly increased in response to
TNF or LPS. However, the level of MCP-1 produced by 4T1 cells
was markedly lower than that produced by LLC cells previously
shown to produce a high level of MCP-1 [27]. Thus, 4T1 cells
have the capacity to produce MCP-1 constitutively or in response
to proinflammatory stimuli, but at a low level. The expression of
CCR2, the receptor for MCP-1, was not detected in 4T1 cells by
either FACS or RT-PCR (Fig. 1C, D). This is consistent with the
previous findings that human breast cancer cells also do not
express CCR2 [28,29].
After intra-mammary injection of 4T1 cells, tumor size
increased at a similar rate in both WT and MCP-12/2 mice at
the injected sites and there was no difference in their weight at 4
weeks (Fig. 2A, B). Interestingly, however, the number of
metastatic tumor nodules in the lung of MCP-12/2 mice was
significant lower compared to that of WT mice (Fig. 2C). MCP-
12/2 mice also survived longer than WT mice (Fig. 2D). These
results indicated that MCP-1 regulates not only carcinogenesis, as
previously reported [11], but also metastatic spread. Our results
also strongly suggested that the main source of MCP-1 in 4T1
tumors was non-tumor cells in tumor stroma.
Non-tumor cells are the major source of MCP-1 in 4T1
tumor
We next determined the cellular source of MCP-1 in 4T1
tumors. As shown in Figure 3A, MCP-1 mRNA was readily
detectable in tumors of WT mice at 2, 3 and 4 weeks after tumor
cell injection, but it was hardly detectable in tumors of MCP-12/2
mice (Fig. 3A). The level of MCP-1 mRNA detected in tumors of
WT mice was clearly higher than that of 4T1 cells stimulated in
vitro with TNF or LPS (Fig. 3B). The level of MCP-1 mRNA
expressed in tumors of MCP-12/2 mice was comparable to that of
in vitro stimulated 4T1 cells (Fig. 3B).
The level of MCP-1 in sera of tumor-bearing mice was also
examined. Sera from non-tumor-bearing WT mice contained
approximately 43 pg/ml of MCP-1. After injection of 4T1 cells,
serum MCP-1 level significantly increased at 1 week, peaked at 3
week and then decreased at 4 week in WT mice. In contrast,
MCP-1 was not detectable in the sera of tumor-bearing
MCP-12/2mice (Fig. 3C). Taken together, these results supported
our assumption that the main source of MCP-1 was not tumor
cells, but non-tumor stromal cells.
MCP-1 produced by both hematopoietic and non-
hematopoietic cells promotes lung metastasis of 4T1
cells
To identify the cell type(s) contributing to the production of
MCP-1 and subsequent lung metastasis of 4T1 cells, we generated
bone marrow chimera mice and examined the lung metastasis of
4T1 cells. Consistent with our results shown above, the numbers of
metastatic tumors in the lung of MCP-12/2 mice that received
MCP-12/2 BM cells (2/2 to 2/2) were significantly lower than
those in the lung of WT mice that received WT BM cells (WT to
WT) (Fig. 3D). The numbers of metastatic tumors detected in the
lung of WT mice that received MCP-12/2 BM cells (2/2 to WT)
and MCP-12/2 mice that received WT BM cells (WT to 2/2)
were similar to those in WT mice that received WT BM cells (WT
to WT). Interestingly, the numbers of metastatic tumors detected
in the lung of MCP-12/2 mice that received WT BM cells (WT to
2/2) were markedly higher than those in the lung of MCP-12/2
mice that received MCP-12/2 BM cells (2/2 to 2/2) (Fig. 3D).
To exclude the possibility that the lack of reduction in lung
metastasis detected in WT mice that received MCP-12/2 BM cells
(2/2 to WT) was due to the incomplete BM chimerism, we
collected BM cells from the representative mice used in this
experiment, isolated genomic DNA and performed Southern
blotting. As shown in Figure 3E, BM cells from all mice showed
the genotype of transplanted BM cells, indicating that BM
chimerism was complete. Thus, MCP-1 produced by both
hematopoietic and non-hematopoietic cells plays a critical role
in promoting the lung metastasis of 4T1 cells, and MCP-1
produced by BM-derived cells, likely macrophages, is sufficient.
Tumor formation of intravenously injected 4T1 cells was
not reduced in the lung of MCP-12/2 mice
It has been reported that early changes in the local microen-
vironment at the metastatic site, termed the ‘‘premetastatic niche’’,
dictate the pattern of metastatic spread [30]. The production of
chemokines at the metastatic site can also regulate metastasis via
interaction with corresponding chemokine receptors expressed on
the surface of tumor cells [29,31]. In our model, MCP-1 is absent
in non-tumor cells at both primary and metastatic sites, and it was
unclear whether the absence of MCP-1 in the lung affected the
capacity of 4T1 cells to metastasize to the lung. To examine this
possibility, we injected 16105 or 46104 4T1 cells intravenously
into WT or MCP-12/2 mice and compared the numbers of tumor
nodules in the lungs after 2 weeks. Similar levels of tumor
formation were detected in the lung of both WT and MCP-12/2
mice (data not shown), supporting the conclusion that MCP-1
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produced in the primary tumors, but not in the lung, was
responsible for the lung metastasis of 4T1 cells.
MCP-1-deficiency in tumor stroma resulted in reduced
macrophage infiltration, deficient angiogenesis, and
early tumor necrosis
As demonstrated above, our results strongly suggested that
MCP-1 produced in the primary tumor microenvironment, but
not in the lung, affected the spontaneous lung metastasis of 4T1
cells. To define the role of MCP-1 in the lung metastasis, we
examined the macroscopic and histological features of primary
tumors growing in WT and MCP-12/2 mice. Although the sizes
of the primary tumors were similar in both WT and MCP-12/2
mice as shown in Figure 2A, we consistently observed early
necrosis of tumors of MCP-12/2 mice and the percentage of the
necrotic area of tumors of MCP-12/2 mice was significantly
higher than that of WT mice (Fig. 4A). The formation of necrotic
lesion was detected as early as 1 week after tumor cell injection
into MCP-12/2 mice at which time necrotic lesion was not
observed in the tumors of WT mice.
Histologically, more intense infiltration of leukocytes was
observed in the subcutaneous area of the tumors in MCP-12/2
mice (Fig. 4B). Immunohistochemical examination revealed that
the infiltration of F4/80 cells was markedly reduced in tumors of
MCP-12/2mice (Fig. 4C). The reduction in the percentage of F4/
80 positive cells in the tumors of MCP-12/2 mice was also found
by flow cytometry analysis (Table 1). In a separate experiment, we
examined the cell population that expresses CD206, a marker for
M2 macrophages. There was no significant difference in the
percentage of CD206-positive cells among F4/80-positive cells
(68.763.2% in WT, n = 3, vs 62.163.9% in MCP-12/2 mice,
n = 3). Conversely, the percentage of CD45+CD11b+Ly6Glow cells
(MDSCs) increased in the tumors of MCP-12/2 mice (Table 1). A
similar shift to neutrophil-rich leukocyte infiltration was previously
found when different tumor cell lines were injected into CCR22/2
mice [32,33]. Finally, positive staining with anti-CD31 Ab was also
decreased in tumors of MCP-12/2 mice. Taken together, our
results indicated that MCP-1 deficiency in tumor stromal cells
resulted in the reduced macrophage infiltration and subsequent
reduced angiogenesis, likely leading to the reduced exit of tumor
cells into blood vessels necessary for lung metastasis.
Elevated MCP-1 production by 4T1 cells has no effect on
their lung metastasis but supports their seeding and
growth in the lung
To examine the cellular source of MCP-1 at the metastatic site,
we evaluated the expression of MCP-1 in the lung of tumor-
bearing WT and MCP-12/2 mice. As shown in Figure 5A, a low
level of MCP-1 mRNA was detectable in the lung of non-tumor-
bearing WT mouse. The level of MCP-1 mRNA was not altered in
the lung of tumor-bearing WT mice up to 3 weeks after injection,
but a significant increase was detected at 4 weeks when metastatic
Figure 1. The expression of MCP-1 and CCR2 by 4T1 cells. A. The expression of MCP-1 mRNA by 4T1 cells was examined and compared to that
of LLC by Northern blotting. B. The concentration of MCP-1 in the culture supernatants of 4T1 or LLC cells incubated for 24 h with 1 or 10 ng/ml of
murine TNFa or 100 ng/ml of LPS or without any stimulus was measured by ELISA. C. The surface expression of CCR2 on 4T1 cells was examined by
FACS. D. The expression of CCR2 mRNA in 4T1 cells was examined by RT-PCR. Thioglycollate-induced mouse peritoneal exudates cells were used as
control.
doi:10.1371/journal.pone.0058791.g001
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tumor nodules were readily visible. As expected, in the lung of
tumor-bearing MCP-12/2mice, MCP-1 mRNA was undetectable
up to 3 weeks; however, unlike the primary tumors, the expression
of MCP-1 mRNA was clearly detectable at 4 weeks, indicating
that the expression of MCP-1 was upregulated in tumor cells.
To determine whether up-regulated MCP-1 expression in
tumor cells that metastasized to the lung was constitutive or in
response to stimuli, we isolated tumor cells from well-isolated
metastatic tumor nodules in the lung of WT or MCP-12/2 mice,
depleting non-tumor cells and then examined the expression of
MCP-1 mRNA in the resulting tumor cells. As shown in Figure 5B,
the majority of tumor cell clones recovered from the metastatic
lung tumors of both WT and MCP-12/2 mice constitutively
expressed higher levels of MCP-1 mRNA and produced higher
levels of MCP-1than the original 4T1 cells, leading to the
hypothesis that higher MCP-1 expression by tumor cells may also
support lung metastasis.
We tested the hypothesis using a subclone of 4T1 cells (4T1-
L10, clone #10 in Fig. 5B) constitutively producing a 10-fold
higher level of MCP-1 compared to the original 4T1 cells or
another subclone 4T1-L5 producing a low level of MCP-1 (clone
#5 in Fig. 5B). We first injected 4T1-L10 cells into the mammary
pad of WT and MCP-12/2 mice. 4T1-L10 cells grew at the same
rate as the original 4T1 cells in both mice at the injected sites
(Fig. 6A). All tumors growing in MCP-12/2 mice developed
marked necrosis 2 weeks after the injection, whereas only one of 4
tumors growing in WT mice showed a small necrotic lesion. This
was similar to the finding when the original 4T1 cells were injected
Figure 2. The absence of MCP-1 in tumor stroma reduces the lung metastasis of 4T1 cells and prolongs survival. A. 16105 4T1 cells
were injected into a mammary pad of WT or MCP-12/2mice. The size of each primary tumor was measured and the area was calculated. n= 9 for WT,
n= 8 for MCP-12/2 mice. B. Primary tumors were excised from WT and MCP-12/2 mice 31 days after tumor cell injection and weighed. n= 9 for WT,
n= 8 for MCP-12/2mice. C. Mice were euthanized on day 31, and lungs were harvested and fixed in Bouin’s solution. The number of metastatic tumor
nodules on the surface of lungs of each mouse was counted by eye. n= 9 for WT, n= 8 for MCP-12/2 mice. D. Ten thousand 4T1 cells were injected in
a mammary pad of each mouse and the survival of each mouse was examined. n= 8 for WT, n= 8 for MCP-12/2 mice.
doi:10.1371/journal.pone.0058791.g002
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in those mice (Fig. 4A). Contrary to our hypothesis, the number of
metastatic tumor nodules in the lung of MCP-12/2 mice
remained low (Fig. 6B). Although MCP-1 mRNA could be
detected readily in the primary 4T1-L10 tumors growing in MCP-
12/2 mice, the levels of MCP-1 mRNA in the primary tumors
were still much lower than those detected in the 4T1-L10 tumors
growing in WT mice (Fig. 6C). The serum MCP-1 concentrations
were also low in tumor-bearing MCP-12/2 mice 2 weeks after the
injection (Fig. 6D). These results indicated that non-tumor cells
were the main source of MCP-1 also in 4T1-L10 tumors and that
tumor cell-derived MCP-1 had little effect on the spontaneous
lung metastasis of 4T1 cells, likely due to the insufficient
angiogenesis.
Next we intravenously injected 4T1-L5 or 4T1-L10 cells into
WT or MCP-12/2 mice. As shown in Figure 6E, intravenous
injection of 4T1-L10 cells resulted in an approximately 2-fold
higher number of tumor nodules in the lung of WT (left panel) and
MCP-12/2 mice (right panel), suggesting that tumor cell-derived
MCP-1 may contribute to the lung metastasis by supporting their
survival and seeding in the lung once tumor cells invade blood
vessels.
Discussion
Metastasis is a multistep process, involving tumor cell migration,
intravasation and survival in circulation, extravasation and
colonization in distant tissues [34]. In order for tumor cells to
initiate the metastatic process, tumor cells must acquire the ability
to migrate and invade, likely through a sequence of genetic and
epigenetic alterations. In addition, non-tumor cells must provide a
microenvironment that favors the seeding, survival and growth of
tumor cells. In IL-1 receptor-deficient [35] or CSF-1-deficient
Figure 3. Non-tumor cells in tumor stroma are the major source of MCP-1. A. 16105 4T1 cells were injected into a mammary pad of WT or
MCP-12/2mice. The expression of MCP-1 mRNA in tumors of WT or MCP-12/2mice was examined by Northern blotting. All RNA samples were run on
a single agarose gel, blotted to a single membrane. The membrane was hybridized to 32P-labeled cDNA probe and exposed to a X-ray film. B. The
level of MCP-1 mRNA expression in a WT and MCP-12/2 tumor was compared with that of 4T1 cells incubated in vitro with or without
proinflammatory stimuli by Northern blotting. C. The serum MCP-1 concentration of tumor-bearing mice 7, 14, 21 or 28 days after tumor cell
inoculation was measured by ELISA. n= 3 per each group at each time point. *p,0.05. D. 16105 4T1 cells were injected into a mammary pad of each
mouse. All mice were euthanized 4 weeks after the injection and lungs were inflated with Bouin’s solution and fixed in the same solution. The
number of metastatic tumor nodules on the surface of the lung of each mouse was counted by eye. n= 4 for each group. E. BM cells were collected
from femurs of mice belonging to each group and genomic DNA was extracted. Ten mg of genomic DNA was digested with BamHI and then
subjected to Southern blot analysis. The 7.5-kb WT allele and the 5.5-kb mutant allele are indicated by arrow heads.
doi:10.1371/journal.pone.0058791.g003
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mice [36] in which tumor microenvironment was markedly altered
by reduced infiltration of leukocytes, spontaneous lung metastasis
of breast cancer cells was significantly reduced. Thus, cooperation
between tumor cells and non-tumor cells in tumor stroma is
critical for tumor metastasis. In the present manuscript, we
demonstrated that MCP-1 produced by stromal cells promotes
Figure 4. MCP-1-deficiency in tumor stroma results in early
necrosis, reduced macrophage infiltration and reduced angio-
genesis. A. 16105 4T1 cells were injected into a mammary pad of WT
or MCP-12/2 mice. Primary tumors were excised two weeks after 4T1
cell injection and fixed in formalin. Tissue sections were prepared from
the center of each tumor, stained by H&E, and the area of necrosis was
measured. % of necrotic area was calculated by using a formula, area of
necrosis/area of tumor6100. n= 5 for each group. B. H&E section of
tumor tissue away from necrosis. C. Immunohistochemical examination
of tumor sections. Green, cytokeratin; Red, F4/80 or CD31.
doi:10.1371/journal.pone.0058791.g004
Table 1. Analysis of tumor-infiltrating leukocyte subsets 3
weeks after 4T1 cell inoculation.
Cell types Markers WT (%) MCP-12/2 (%)
Myeloid cells CD45+CD11b+ 90.660.5 94.360.5**
MDSCs CD45+CD11b+Ly6Glow 21.561.2 26.060.5*
Macrophages CD45+CD11b+F4/80+ 15.862.0 6.160.8***
Tumors were excised and digested by collagenase IV for 2 hrs at room
temperature. Cell suspensions were filtered and red blood cells were depleted
with ACK solution. Cells were stained by monoclonal antibodies against mouse
CD45 labeled by PECy5.5, CD11b labeled by PE, Ly6G labeled by FITC or F4/80
labeled by FITC, and the expression of each molecule was analyzed using a
FACScan flow cytometer. n= 3,
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0058791.t001
Figure 5. 4T1 cells that metastasized to the lung express higher
level of MCP-1. A. 16105 4T1 cells were injected into a mammary pad
of WT or MCP-12/2 mice. Total RNA was extracted from the lung of
tumor-bearing WT or MCP-12/2 mice and the expression of MCP-1
mRNA was examined by Northern blotting. B. Total RNA was extracted
from 4T1 cells obtained from metastatic lung tumors of WT or
MCP-12/2 mice and the expression of MCP-1 mRNA was evaluated by
Northern blotting (upper panel). 16105 cells were seeded into 12-well
plates and incubated at 37uC overnight. Medium was replaced by 1 ml
fresh medium and incubated for an additional 24 hrs. Cell-free culture
supernatants were collected and the concentrations of MCP-1 were
measured by ELISA (lower panel). * p,0.01, n = 2.
doi:10.1371/journal.pone.0058791.g005
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lung metastasis of 4T1 breast cancer cells by providing a
microenvironment that favors metastasis.
The production of MCP-1 was previously examined in human
breast cancer tissues. Both tumor cells and stromal cells in the
tumor, such as lymphoreticular cells, fibroblasts, endothelial cells
and macrophages, were positive for MCP-1 by immunohisto-
chemistry [21,22,37]. The expression of MCP-1 in tumor cells
showed a significant correlation with the level of thymidine
phosphorylation and membrane type 1-matrix metalloproteinase
expression [21], whereas MCP-1 expression in macrophages in
tumor stroma correlated with the level of microvessel density and
vessel invasion of tumor cells. These observations of human breast
cancer tissues are consistent with our results obtained with the 4T1
mouse breast cancer model, indicating that our model is clinically
valid.
Studies of bone marrow chimeras indicated that both hemato-
poietic and non-hematopoietic cells contributed to the MCP-1
production, and that MCP-1 produced by either cell population
Figure 6. Increased MCP-1 expression in 4T1 cells has no effect on spontaneous lung metastasis in MCP-12/2 mice, but increases
lung metastasis after intravenous injection. A. 16105 4T1-L10 cells were injected into a mammary pad of WT or MCP-12/2 mice. The size of
each primary tumor was measured and the area was calculated. n= 4 for WT, n= 3 for MCP-12/2 mice. B. 16105 4T1-L10 cells were injected into a
mammary pad of WT or MCP-12/2 mice. All mice were euthanized 4 weeks after the injection and the number of metastatic tumor nodules on the
surface of each lung was counted by eye. C. Total RNA was extracted from each tumor and the expression of MCP-1 mRNA was examined by
Northern analysis. Ten mg of total RNA was used. D. Sera were collected 2 weeks after the injection of 4T1-L10 cells and MCP-1 concentrations were
measured by ELISA. E. 4T1-L5 or 4T1-L10 cells (56104 cells in 0.2 ml PBS) were intravenously injected into WT (left panel) or MCP-12/2 mice (right
panel). Two weeks later, mice were euthanized and the number of metastatic tumor nodules on the lung was counted. The results are the summary
of two independent experiments. n= 8 for WT, and n= 8 (4T1-L5) or n= 9 (4Y1-L10) for MCP-12/2 mice.
doi:10.1371/journal.pone.0058791.g006
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was sufficient to promote lung metastasis of 4T1 cells. Among
hematopoietic cells, macrophages have been shown to facilitate the
malignant transformation of mammary tumors and their pulmo-
nary metastasis. For example, in the absence of CSF-1, the
transformation and growth of the primary tumors in polyoma
middle T antigen (PyMT) mice was not affected, but the
recruitment of macrophages and the progression to malignancy
and the metastatic spread were significantly reduced [36]. In vivo
chemotaxis assay suggested that epidermal growth factors and
CSF-1, but not MCP-1, were the chemotactic factors responsible
for the recruitment of macrophages into tumors [38,39]. As noted
above, MCP-1 was originally purified from tumor cell lines as a
chemoattractant responsible for the recruitment of TAMs [3–5]. A
direct correlation between the expression of MCP-1 and
macrophage infiltration was previously detected in human breast
cancer tissues and neutralization of MCP-1 significantly decreased
the number of tumor-infiltrating macrophages [21,22,37]. In our
study, the infiltration of macrophages into tumors was markedly
reduced in the absence of MCP-1, indicating that MCP-1 is one of
the critical chemoattractants for the recruitment of macrophages
into tumors, such as breast cancer, and that macrophages
themselves are one of the major sources of MCP-1.
Our studies revealed that the primary tumors of MCP-12/2
mice develop necrosis significantly earlier than those of WT mice
and that the blood vessel formation was markedly reduced in
tumors of MCP-12/2 mice. MCP-1 can indirectly promote
angiogenesis by recruiting monocytes, which in turn release
angiogenic factors, such as VEGF [37,40]. MCP-1 can also
directly promote angiogenesis by activating the migration and Ets-
1 transcription factor in endothelial cells [41,42], and by recruiting
smooth muscle cells toward endothelial cells [43]. Thus, it is likely
that MCP-1-deficiency in tumor stroma resulted in reduced
angiogenesis and intravasation of tumor cells, leading to reduced
lung metastasis.
The expression of MCP-1 by stromal cells suggests that they are
activated by the product(s) of 4T1 cells. 4T1 cells were previously
shown to express transcripts for CSF-1, 2 and 3, and CSF-1 has
the capacity to induce MCP-1 production in leukocytes, such as
macrophages [44]. When 4T1 cells were inoculated into the
mammary pad of interleukin -1 receptor (IL-1R)-deficient mice,
the levels of cytokines, including IL-6, TNFa and MCP-1, in the
tumor tissue were significantly reduced and both tumor progres-
sion and lung metastasis were reduced [35]. In another study, co-
culture of mouse macrophages with the human MDA-MB-231
breast cancer cells in vitro upregulated MCP-1 production by
mouse macrophages [22]. These previous findings suggest that
breast cancer cells release mediators, such as CSF-1 and IL-1, to
activate tumor-infiltrating macrophages to produce MCP-1. We
recently observed that the culture supernatant of 4T1 cells was
capable of inducing MCP-1 production in mouse macrophages,
independent of IL-1, IL-6, TNFa, or CSF-1 (Yoshimura,
unpublished data). Identifying the molecule(s) responsible for the
induction of MCP-1 in macrophages by cancer cells may provide a
new means to target tumor microenvironment.
It was previously demonstrated that at metastatic sites, a distinct
population of metastasis-associated macrophages promotes the
extravasation, seeding and persistent growth of tumor cells
[45,46]. Qian et al. recently identified the phenotype of these
macrophages as Gr1+ inflammatory macrophages expressing
CCR2. Neutralization of MCP-1 derived from either tumor cells
or stromal cells blocked the recruitment of inflammatory
monocytes, inhibited lung metastasis of breast cancer cells and
prolonged the survival of tumor-bearing mice [46]. In our study,
the lung metastasis of intravenously injected 4T1 cells in
MCP-12/2 mice was comparable to that in WT mice; thus
circulating 4T1 cells appear to metastasize to the lung indepen-
dently of MCP-1 produced by lung tissues. However, tumor cells
are heterogeneous and tumor cells producing higher levels of
MCP-1 may have an advantage in metastasizing to the lung. In
fact, the levels of MCP-1 expressed in 4T1 cells recovered from
metastatic tumor nodules in the lung of WT or MCP-12/2 mice
were higher than that of the original in vitro cultured 4T1 cells.
Furthermore, intravenous injection of 4T1-L10 cells producing a
10-fold higher level of MCP-1 resulted in increased lung metastasis
in both WT and MCP-12/2 mice. Thus, tumor cells with the
capacity to produce higher levels of MCP-1 show better survival
and seeding in a remote metastatic site. Additional studies are
necessary to determine the mechanisms by which MCP-1
expression is constitutively upregulated in metastasized 4T1 cells.
We previously reported that the expression and production of
MCP-3/CCL7, which is highly similar to MCP-1 and attracts
monocytes through CCR2 [47,48], were up-regulated in our
MCP-12/2 mice [24]; therefore, the low level lung metastases
detected in MCP-12/2 mice might be due to the increased MCP-
3 production. As expected, the expression of MCP-3 mRNA was
markedly higher in tumors of MCP-12/2 mice than those of WT
mice. The serum MCP-3 levels were also significantly elevated in
MCP-12/2 mice and the sums of MCP-1 and MCP-3 serum
concentrations in tumor-bearing WT and MCP-12/2 mice were
comparable (data not shown). These results indicated that
increased MCP-3 production in MCP-12/2 mice was not
sufficient to compensate for the loss of MCP-1 and strongly
suggested that MCP-3 does not play a significant role in the lung
metastasis of 4T1 cells. We did not examine the production of
MCP-5/CCL12, another CCR2 ligand. Interestingly, the number
of metastatic tumor nodules in the lung of CCR22/2 mice was not
significantly different from that of MCP-12/2 mice (data not
shown). MCP-5 was recently shown not to be involved in the
recruitment of metastatic macrophages in a mouse breast cancer
model [46]. Therefore, MCP-5 does not appear to play a role in
the lung metastasis of 4T1 cells. Thus, although all three MCP’s
bind CCR2 and induce monocyte migration in vitro, MCP-1 is the
responsible CCR2 ligand in vivo, in particular, in tumor
metastasis.
In contrast to its prometastatic role, MCP-1 was recently
reported to also promote an anti-metastatic host response [49].
Gr1+ neutrophils accumulated in the lung prior to the arrival of
metastatic cells in mouse models of breast cancer, including mouse
4T1 model. Interestingly, neutrophils were entrained to inhibit
metastatic seeding in the lung by generating H2O2 and tumor-
secreted MCP-1 was a critical mediator of anti-metastatic
entrainment of G-CSF-stimulated neutrophils. In our study, the
metastasis of 4T1 cells to the lung was markedly reduced in MCP-
12/2mice, indicating that MCP-1-mediated neutrophil entraining
does not play a significant role. Nevertheless, we found that an
increased number of neutrophils infiltrated in the marginal areas
of primary tumors of MCP-12/2 mice, which may represent anti-
tumor progression and anti-metastasis host responses in the
absence of MCP-1.
In conclusion, we have demonstrated that non-tumor stromal
cells play a critical role in the spontaneous lung metastasis of 4T1
breast cancer cells by providing a high level of MCP-1 which
facilitates angiogenesis by recruiting pro-angiogenic macrophages
and perhaps by directly acting on endothelial cells. Tumor cell-
derived MCP-1 has no effect on spontaneous lung metastasis of
4T1 cells; however, it can contribute to the lung metastasis by
supporting tumor cell survival and seeding in the lung once tumor
cell invade blood vessels. Thus, MCP-1 produced by stromal cells
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and tumor cells orchestrates the metastatic process of 4T1 cells.
Targeting MCP-1 may reduce lung metastasis of breast cancer
cells.
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